Hara Capital LLC Invests $913,000 in Bio-Rad Laboratories, Inc. $BIO

Hara Capital LLC acquired a new stake in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm acquired 3,255 shares of the medical research company’s stock, valued at approximately $913,000.

Other large investors also recently modified their holdings of the company. Universal Beteiligungs und Servicegesellschaft mbH increased its stake in Bio-Rad Laboratories by 54.0% in the 3rd quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 12,956 shares of the medical research company’s stock worth $3,633,000 after buying an additional 4,541 shares in the last quarter. Inscription Capital LLC bought a new position in shares of Bio-Rad Laboratories in the third quarter worth about $389,000. Wealth Enhancement Advisory Services LLC grew its position in shares of Bio-Rad Laboratories by 13.5% during the third quarter. Wealth Enhancement Advisory Services LLC now owns 1,073 shares of the medical research company’s stock worth $318,000 after purchasing an additional 128 shares in the last quarter. Campbell & CO Investment Adviser LLC bought a new stake in Bio-Rad Laboratories during the 3rd quarter valued at approximately $628,000. Finally, Quent Capital LLC bought a new stake in Bio-Rad Laboratories during the 3rd quarter valued at approximately $25,000. Hedge funds and other institutional investors own 65.24% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have issued reports on BIO. Citigroup increased their price objective on shares of Bio-Rad Laboratories from $350.00 to $375.00 and gave the company a “buy” rating in a report on Thursday, October 30th. Wall Street Zen upgraded shares of Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a research report on Saturday, January 10th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Bio-Rad Laboratories in a report on Monday, December 29th. Finally, Wells Fargo & Company raised their price objective on Bio-Rad Laboratories from $265.00 to $340.00 and gave the company an “equal weight” rating in a research report on Thursday, October 30th. Three research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $358.50.

Insider Transactions at Bio-Rad Laboratories

In other Bio-Rad Laboratories news, EVP James Barry sold 700 shares of the company’s stock in a transaction that occurred on Thursday, November 6th. The stock was sold at an average price of $306.18, for a total transaction of $214,326.00. Following the sale, the executive vice president directly owned 510 shares in the company, valued at $156,151.80. This represents a 57.85% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link. 17.06% of the stock is currently owned by company insiders.

Bio-Rad Laboratories Price Performance

Bio-Rad Laboratories stock opened at $304.94 on Friday. Bio-Rad Laboratories, Inc. has a 52-week low of $211.43 and a 52-week high of $373.69. The company has a quick ratio of 3.94, a current ratio of 5.44 and a debt-to-equity ratio of 0.18. The firm’s fifty day moving average is $312.71 and its 200 day moving average is $296.08. The company has a market cap of $8.23 billion, a price-to-earnings ratio of -12.54 and a beta of 1.18.

Bio-Rad Laboratories (NYSE:BIO) last posted its earnings results on Wednesday, October 29th. The medical research company reported $2.26 earnings per share for the quarter, missing analysts’ consensus estimates of $2.30 by ($0.04). Bio-Rad Laboratories had a positive return on equity of 4.19% and a negative net margin of 26.43%.The business had revenue of $653.00 million during the quarter, compared to the consensus estimate of $651.30 million. During the same quarter last year, the firm earned $2.01 earnings per share. The business’s quarterly revenue was up .5% on a year-over-year basis. Sell-side analysts forecast that Bio-Rad Laboratories, Inc. will post 10.81 EPS for the current fiscal year.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc is a global provider of life science research and clinical diagnostic products. The company operates through two primary business segments: Life Science and Clinical Diagnostics. Within the Life Science segment, Bio-Rad offers instruments, reagents and consumables for protein analysis, cell biology, gene expression and other molecular biology applications. The Clinical Diagnostics segment supplies quality control products, blood-typing reagents and instruments, and molecular diagnostic assays used in blood screening, infectious disease testing and routine clinical laboratories.

Founded in 1952 by David and Alice Schwartz and headquartered in Hercules, California, Bio-Rad has grown its footprint across the Americas, Europe, Asia-Pacific and other regions.